Hiệu quả kháng ung thư của virus vaccine sởi trên mô hình chuột thiếu hụt miễn dịch mang khối ung thư phổi người

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Duy Cương Lê, Thu Hằng Ngô, Lĩnh Toàn Nguyễn, Thị Mỹ Thành Nguyễn, Văn Đô Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại: 362.196979 Physical illness

Thông tin xuất bản: Tạp chí Nghiên cứu y học (Đại học Y Hà Nội), 2022

Mô tả vật lý: 317-323

Bộ sưu tập: Metadata

ID: 499885

Thêm vào giỏ

Đánh giá hiệu quả kháng ung thư của virus vaccin sởi trên chuột thiếu hụt miễn dịch mang khối ung thư phổi người (dòng H460). Virus vaccin sởi (MeV) được tách dòng từ vaccin Priorix (Glaxosmith Kline, Anh) và tăng sinh trong phòng thí nghiệm. Chuột thiếu hụt miễn dịch (nude mouse, Hoa Kỳ) 6 - 8 tuần tuổi, số lượng 20 con, được tiêm ghép 106 tế bào H460 (ATCC, Hoa Kỳ) vào dưới da đùi sau để tạo khối ung thư phổi người trên chuột nude. Khi khối u có kích thước khoảng 50 - 70mm3 (sau 10 ngày ghép), chuột được chia thành 2 nhóm (10 con/nhóm), nhóm điều trị được tiêm trực tiếp MeV vào khối u với liều 107 CFU/con, 2 lần/tuần, trong 3 tuần liên tiếp, nhóm chứng tiêm dung dịch PBS. Nhóm chuột mang khối ung thư phổi người H460 được điều trị bằng MeV có thể tích khối u nhỏ hơn, thời gian sống dài hơn và tỉ lệ chuột chết ít hơn so với nhóm chứng (p <
0,05). Kết quả nghiên cứu cho thấy MeV có hiệu quả kháng ung thư phổi người trên mô hình chuột thiếu hụt miễn dịch mang khối ung thư ghép dị loài.This study aims to evaluate the anti-cancer effect of the measles virus vaccine on immunodeficient mice bearing human lung tumors (H460 cell line). The measles vaccine (MeV) was isolated from the Priorix vaccine (Glaxosmith Kline, UK). Twenty nude mice, USA, aged six to eight week-old, were injected subcutaneously into hind thighs with 106 H460 cells (ATCC, USA). When the tumor size reached 50 - 70 mm3 (post-transplant of ten days), the mice were divided randomly into two groups (10 mice/group). The treatment group was injected directly into the tumors by MeV with a dose of 107 CFU/mouse twice weekly for three weeks, and the control group was injected into the tumors by PBS. The virus-treated group had a smaller volume of tumors, a longer survival time, and a lower mortality rate than the control group (p <
0.05). The results indicated that MeV had anti-cancer efficacy against human lung cancer on immunodeficient mouse model bearing xenograft tumors.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR